Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis-Reference-Cited by-同舟云学术

Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis

Published:2016-04-23 Issue:2 Volume:128 Page:185-194
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Choi Sang Hyun,Jung Seung Chai,Kim Kyung Won,Lee Ja Youn,Choi Yoonseok,Park Seong Ho,Kim Ho Sung

Funder

Asan Institute for Life Sciences of Asan Medical Center

The National Research Foundation of Korea (NRF)

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Neurology,Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-016-2102-4.pdf

Reference28 articles.

1. Aquino D, Di Stefano AL, Scotti A, Cuppini L, Anghileri E, Finocchiaro G, Bruzzone MG, Eoli M (2014) Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS ONE 9(3):e90535. doi: 10.1371/journal.pone.0090535

2. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28(18):3069–3075. doi: 10.1200/jco.2009.26.8789

3. Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncology 13(10):1143–1150. doi: 10.1093/neuonc/nor091

4. Lavini C, Verhoeff JJ, Majoie CB, Stalpers LJ, Richel DJ, Maas M (2011) Model-based, semiquantitative and time intensity curve shape analysis of dynamic contrast-enhanced MRI: a comparison in patients undergoing antiangiogenic treatment for recurrent glioma. J Magn Reson Imaging: JMRI 34(6):1303–1312. doi: 10.1002/jmri.22742

5. Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL (2015) Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro-oncology 17(8):1148–1156. doi: 10.1093/neuonc/nou364

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the neoadjuvant chemotherapy response in osteosarcoma using the MRI DWI-based machine learning radiomics nomogram;Frontiers in Oncology;2024-03-21

2. MR Perfusion Imaging for Gliomas;Magnetic Resonance Imaging Clinics of North America;2024-02

3. Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis;Diagnostic and Interventional Radiology;2024-02-01

4. Multimodel habitats constructed by perfusion and/or diffusion MRI predict isocitrate dehydrogenase mutation status and prognosis in high-grade gliomas;Clinical Radiology;2024-01

5. Relative cerebral blood volume as response predictor in the treatment of recurrent glioblastoma with anti-angiogenic therapy;Clinical Neurology and Neurosurgery;2023-10